Comanche Biopharma is thrilled to announce that it has successfully raised $90,000,000 in its latest funding round, marking a pivotal moment in its mission to revolutionize maternal healthcare. As a leading biopharmaceutical company, Comanche is committed to developing an investigational siRNA medicine specifically targeted at preterm preeclampsia—a life-threatening complication during pregnancy. This groundbreaking funding will enable the company to expand its clinical trials and accelerate the development of its innovative therapy, thereby advancing toward its vision of ensuring that all women and their babies have access to safe and effective treatments. The significant capital injection not only validates the promise of Comanche’s therapeutic approach but also underlines investor confidence in the potential of precision medicine in addressing complex pregnancy complications. With this new financial boost, the company plans to deepen its research initiatives, streamline manufacturing processes, and enhance regulatory engagements, paving the way for robust evidence-based solutions. Comanche’s dedication to affordability further underscores its commitment to making lifesaving therapies accessible to diverse populations around the globe. This milestone funding is an essential step forward in overcoming the challenges associated with preterm preeclampsia and reflects the broader shift toward innovative, targeted treatments in maternal-fetal medicine. As the company harnesses this momentum, stakeholders can look forward to a new era where cutting-edge technology and compassionate care converge to transform outcomes for mothers and babies alike, setting a new benchmark in the field of biopharmaceutical innovation.

Comanche Biopharma Secures $90M Series B to Advance Groundbreaking siRNA Therapy for Preterm Preeclampsia
Get the full Comanche Biopharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com
$150.0M Unknown
today

Lunar Outpost
Lunar Outpost is the industry leader in commercial space robotics, lunar surface mobility, and in-space infrastructure. We are on a mission to enable an extended human presence in space while utilizing the vast resources in space to drive positive impacts here on Earth. From our five rovers headed to the Moon to explore, prospect, and establish infrastructure, to the creation of oxygen on Mars, our impact spans the solar system. Lunar Outpost’s mobility and robotic systems, ranging from our exploration-class Mobile Autonomous Prospecting Platform (MAPP) rover to our truck-sized industrial Lunar Terrain Vehicle (LTV), will be the workforce for the New Space economy and enable Lunar Outpost to bring the infinite value of space to benefit humanity on Earth and beyond. Through notable commercialization and amazing partnerships, Lunar Outpost creates tremendous value in the New Space economy. Lunar Outpost leads the Lunar Dawn team, consisting of General Motors, Goodyear, and MDA Space – the leading consortium for LTV providing mobility for Artemis astronauts, a critical component of the broader Artemis campaign that will enable a sustainable presence on the Moon. Lunar Outpost’s five upcoming lunar surface missions will make history, with our first rover set to be the first commercial rover on the Moon and the first rover in history to explore the lunar South Pole, while enabling the first sale of space resources in human history alongside many other firsts. Each of our next four rover voyages build on our capabilities and technology, all leading towards mobility and robotic systems that can reliably operate in the most extreme environments our solar system has to offer.
$30.0M Series b
today

Darkhive
Darkhive develops US-produced open autonomous robotics systems for the defense and public safety communities.
$30.0M Series b
today

Founders First Capital Partners
National lender serving BIPOC, veteran, LGBTQ+, & women-owned businesses, as well as businesses in LMI zones & those committed to diverse hiring practices. Helping accelerate business growth through our Revenue-Based Funding products & Advisory Services. Together, we can create more jobs, increase your revenues and bottom line, and provide more growth capital to help your business. We’re backed by the nation’s top philanthropic organizations, so that we can fund you with the right capital.
$3.9M Unknown
today

Nelson
We help companies reduce their carbon footprints, control their mobility costs and use energy more efficiently. Our data-driven software enables companies to plan, deploy and operate a successful electrification strategy for their car fleet. Nelson combines companies' fleet data and the charging ecosystem data to provide personalized recommendations -in real time & automatically.
$3.5M Seed
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Lunar Outpost United States | Series b | $30.0M | today |
| 2 | ![]() Darkhive United States | Series b | $30.0M | today |
| 3 | ![]() GoKwik | Series b | $22.5M | today |
| 4 | ![]() EnviroSpark Energy Solutions United States | Series b | $3.0M | 1d ago |
| 5 | ![]() Moonshot AI United States | Series b | $2.0B | 1d ago |


